Key statistics dashboard for BioCardia, Inc. (BCDA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions.
Stock Data
| Price | $1.25 |
| Market Cap | $19M |
| Beta | 0.55 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.62 |
| Price / Book | 5.51 |
| P/S | 0.00 |
| P/FCF | -2.42 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.09 |
| Quick Ratio | 2.09 |
| Cash Ratio | 2.00 |
| Debt / Equity | 0.11 |
| Debt / Assets | 6.16% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -74.97 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.22 |
| Cash per share | 0.34 |
| FCF per share | -0.63 |
| Tangible Book Value per share | 0.22 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Related companies: ACXP · ADIL · ALZN · APRE · APVO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of BCDA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks